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Abstract
The objective of this study was to investigate the occurrence of vancomycin-resistant Enterococcus (VRE) cross-transmission 
between two patient groups (long-term dialysis and kidney transplant patients). Molecular typing, by automated ribotyping with 
the RiboPrinter Microbial Characterization System (Qualicon, USA), was used to analyze VRE isolates from 31 fecal samples 
of 320 dialysis patients and 38 fecal samples of 280 kidney transplant patients. Clonal spread of E. faecalis and E. casseliflavus 
was observed intragroup, but not between the two groups of patients. In turn, transmission of E. gallinarum and E. faecium 
between the groups was suggested by the finding of vancomycin-resistant isolates belonging to the same ribogroup in both 
dialysis and transplant patients. The fact that these patients were colonized by VRE from the same ribogroup in the same 
health care facility provides evidence for cross-transmission and supports the adoption of stringent infection control measures 
to prevent dissemination of these bacteria.
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Cross-transmission of multidrug-resistant organisms 
(MDRO), very often via hands of health care workers, has 
been a major factor accounting for the increase in MDRO 
incidence and prevalence, especially for methicillin-resistant 
Staphylococcus aureus and vancomycin-resistant entero-
cocci (VRE) in acute care facilities (1). Among the many spe-
cies of MDRO, enterococci have emerged as increasingly 
important nosocomial and community-acquired pathogens, 
since their tolerance against harsh conditions renders them 
difficult to control in health care environments (2,3). 
VRE infection has become a matter of great concern 
in patients with end-stage renal disease in America and 
Europe, and it has significantly contributed toward increas-
ing the morbidity and mortality within this population (4). 
In 2003, VRE was identified in dialysis and renal trans-
plant patients at the Universidade Federal de São Paulo 
nephrology service. The prevalence of colonization was 
14.4% in dialysis patients, with type of dialysis treatment 
(hemodialysis vs peritoneal dialysis), hospital admission and 
length of hospital stay identified as risk factors. In kidney 
transplant patients, the observed prevalence was 13.6%, 
and none of these risk factors were identified (4,5). This 
observation strongly suggests the occurrence of nosocomial 
cross-transmission. 
The aim of this study was to investigate the occurrence of 
VRE cross-transmission between patients undergoing long-
term dialysis and kidney transplant patients at UNIFESP.
Material and Methods
This cross-sectional study was approved by the Re-
search Ethics Committee at UNIFESP. All patients provided 
written informed consent for storage and later use of their 
biological materials.
Two to four samples of feces were collected in steril-
ized receptacles from each patient once a week during a 
116 D. Fram et al.
www.bjournal.com.brBraz J Med Biol Res 43(1) 2010
1-month period. Thirty-one VRE isolates were obtained from 
feces of 320 dialysis patients, and 38 VRE isolates from 
feces of 280 kidney transplant patients (4,5). VRE samples 
were stored at -20°C in glycerol media at the UNIFESP 
Special Clinical Microbiology Laboratory until retrieval for 
the present study. 
Between December 2007 and July 2008, these VRE 
isolates were submitted to further characterization in azide 
blood agar supplemented with 6 μg/mL vancomycin (6). 
They were identified at the species level by conventional 
biochemical tests as described by Facklam et al. (7). Van-
comycin resistance was confirmed by disk diffusion and 
the E-test (AB Biodisk, Sweden) according to Clinical and 
Laboratory Standards Institute (CLSI) breakpoints (8). 
Molecular typing
Molecular typing was performed by automated ribotyp-
ing, employing the RiboPrinter Microbial Characterization 
System (Qualicon, USA). This automated process includes 
cell lysis, DNA cleavage by restriction enzymes (EcoRI), and 
band separation using electrophoresis gel and the modified 
Southern blot technique. DNA fragments were hybridized 
with a labeled universal probe derived from ribosomal RNA 
from Escherichia coli, and bands were detected by means 
of a luminescent chemical substrate. Images were captured 
on a camera and electronically transferred to a computer 
coupled to the ribotyping system. Every line representing 
sample data was normalized in accordance with a standard 
marker based on the intensity of the bands.
 
The coefficient 
of similarity was calculated by the computing system on 
the basis of the position and relative weight of the bands. 
All samples with band patterns presenting a coefficient of 
similarity ≥0.90 were included in the same ribogroup. The 
samples with coefficients of similarity below 0.90 were 
classified into distinct ribogroups (9). 
Dendrogram analysis
The identified ribogroups were exported as a TIFF file 
and imported into the BioNumerics™ software (Applied 
Maths, Belgium). The patterns were normalized based 
on the mobility of standards, and a similarity matrix was 
created. The clustering was developed on the basis of the 
unweighted pair group method with arithmetic averages 
(UPGMA). The Dice correlation coefficient was used to 
analyze the similarities of the banding patterns. Based 
on the use of internal controls in the database, pattern 
optimization and band position tolerance of 0.8 and 1.0, 
respectively, were allowed.
Results
The following species were identified by automated 
ribotyping in 31 VRE isolates from dialysis patients: E. 
faecalis (N = 2), E. casseliflavus (N = 5), E. faecium (N = 9), 
and E. gallinarum (N = 15). In the 38 samples from kidney 
transplant patients, E. faecalis (N = 10), E. casseliflavus 
(N = 10), E. faecium (N = 10), and E. gallinarum (N = 8) 
were observed.
Following automated ribotyping, computational analysis 
using the BioNumerics™ software was used to compare 
typing data for all bacterial isolates in order to group the 
organisms according to degree of similarity. This allows 
determination of clusters sharing a common source of 
infection. A similarity coefficient of 80% was selected to 
define ribogroup clusters after reviewing the epidemiologic 
data associated with each of the clusters of MDRO clones 
(10-12). Thirty-five ribogroups were found: E. faecalis with 3 
ribogroups, E. casseliflavus with 14 ribogroups, E. faecium 
with 13 ribogroups, and E. gallinarum with 7 ribogroups. 
E. faecium 112-S-4 was observed in 4 hemodialysis 
patients and in 1 transplant patient. As shown in Figure 1A, 
these samples had a coefficient of similarity >83%, suggest-
ing clonal dissemination. The predominant ribogroup was 
E. gallinarum 112-S-4, which colonized 13 hemodialysis 
patients and four transplant patients, with a 92% coefficient 
of similarity, again suggesting clonal dissemination between 
the two patient groups. Furthermore, ribogroup 116-S-3 
observed in one kidney transplant patient showed more 
than 84% similarity with the 112-S-4 ribogroup, indicating 
a possible relationship between these samples (data not 
shown). 
The largest ribogroup diversity was observed for E. cas-
seliflavus samples. Nevertheless, only one E. casseliflavus 
ribogroup, namely 112-S-4, was detected in two kidney 
transplant samples (intragroup transmission). It should be 
noted, however, that dendrogram analysis of the E. casse-
liflavus 112-S-4 ribogroup revealed a coefficient of similarity 
of 87% with the 115-S-4 ribogroup from hemodialysis patient 
samples (data not shown). Despite the fact that these are 
different ribogroups, this finding also supports the notion of 
cross-transmission between the two patient groups.
Of the E. faecalis samples from kidney transplant pa-
tients, nine were classified in the same ribogroup, 112-S-4. 
Only one sample was classified as belonging to a distinct 
ribogroup, 118-S-6. Interestingly, these ribogroups had 
a similarity >87%, suggesting cross-transmission of this 
pathogen within the transplant group. Based on dendrogram 
analysis, it is possible to confirm intragroup clonal spread 
of E. faecalis in hemodialysis patients, but not between the 
dialysis and transplant groups (Figure 1B). 
Discussion
VRE infection is a growing problem in specific groups 
of patients. According to the National Healthcare Safety 
Network, 26% of blood cultures in outpatient dialysis are 
caused by VRE (13).
The resistance to glycopeptides might be mediated 
by various gene clusters: vanA, vanB, vanC, vanD, vanE, 
vanG, and vanL (14). VanA-related clusters have high-
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Figure 1. A, Dendrogram analysis of Enterococcus faecium ribogroups isolated from dialysis (DL) and kidney transplant patients (KT). 
B, Dendrogram analysis of E. faecalis ribogroups isolated from DL and KT patients.
A
B
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level resistance to vancomycin and teicoplanin (15). VanB 
isolates were believed to be inducibly resistant to lower 
levels of vancomycin; however, the range of resistance has 
been reported to be fairly broad (4 to ≥1000 μg/mL) and 
susceptibility to teicoplanin is retained (16).
Gene resistance is mediated by mobile elements (plas-
mids) that can be transferred from one strain of Enterococ-
cus to another. VanA- and vanB-resistant phenotypes have 
been described primarily in E. faecalis and E. faecium, 
which are responsible for most enterococcal infections and 
nosocomial VRE outbreaks, usually carried by gene vanA. 
E. gallinarum and E. casseliflavus are also occasionally 
responsible for infections (15).
In the present study, we showed that dialysis and kidney 
transplant patients were colonized with similar vancomycin-
resistant E. faecium and E. gallinarum ribogroups. VRE has 
become an important nosocomial pathogen because of its 
rapid spread, high mortality rates associated with infections, 
limited options for treatment and the possibility of transferring 
the vanA resistance gene to other more virulent and more 
prevalent pathogens, such as S. aureus (17). 
McNeil et al. (18) showed that patients who acquired 
VRE after transplant had worse outcomes than those with 
VRE colonization documented before transplant (longer 
duration of hospitalization and intensive care unit stay and 
higher mortality rates). Mathematical modeling studies 
have been used to estimate the impact of active surveil-
lance cultures to control MDRO. One such study evaluat-
ing interventions to decrease VRE transmission indicated 
that use of active surveillance cultures, versus no cultures, 
could potentially decrease transmission by 39%, and that 
with pre-emptive isolation plus active surveillance cultures 
transmission could be decreased by 65% (19).
Our results show the VRE cross-transmission occurred 
between the two patient groups analyzed, kidney transplant 
and hemodialysis patients. Patient-to-patient transmission 
in health care settings has been a major factor accounting 
for the increase in VRE incidence and prevalence. In a 
study conducted by Padiglione et al. (20), the analysis of 
VRE strains isolated in an acute-care hospital suggested 
that most isolates were non-clonal on pulsed-field gel 
electrophoresis (PFGE), and that the strict infection control 
procedures that were in place at each study site were rea-
sonably effective in preventing the nosocomial transmission 
of dominant clones. Nevertheless, the fact that some strains 
had similar PFGE patterns suggests that hospital-related 
transmission of VRE cannot be ruled out. 
In our patients, the finding of E. faecium and E. faecalis 
strains with the same or similar molecular profiles by ribotyp-
ing strongly suggests patient to patient transmission by a 
common source, justifying the implementation of strict bar-
rier measures. Freitas et al. (5) observed an unexpectedly 
high rate of VRE colonization in kidney transplant patients, 
which is very similar to that observed in intensive care units. 
Furthermore, a high rate of VRE colo nization was observed 
in outpatients, raising the ques tion of whether surveillance 
should be extended to recently admitted patients. Due to 
the high costs involved in surveillance culture, this strategy 
could be reserved for patients with known risk factors, or 
for those with a higher probability of transmission.
Some measures must be established to prevent the 
emergence and transmission of VRE. These include en-
vironmental measures such as cleaning and disinfection 
of patient care areas and equipment, single-patient use of 
non-critical equipment, and decolonization therapy when 
appropriate. Other useful measures include adequate di-
mensioning of the nursing staff, communication systems, 
education and training of medical and other healthcare per-
sonnel, judicious antibiotic use, performance improvement 
processes to ensure adherence to recommended infection 
control procedures, and comprehensive surveillance for 
application of MDRO infection control precautions during 
patient care (19).
Cross-transmission of VRE was observed between two 
groups of patients at a university hospital. It is possible 
that the dissemination of MDRO reported in this study may 
have been caused by factors that can be modified so as to 
benefit patients, staff, and the institution.
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